Tumor Cell Expression of PD-L1 is Key in Predicting Efficacy of Pembrolizumab for Patients With mTNBC


The analysis of the KEYNOTE-119 study presented at the Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC®, found trends estimating a significant role for tumor cell expression in PD-L1 as a predictive biomarker for pembrolizumab efficacy.

Data from the KEYNOTE-119 study (NCT02555657) produced estimated trends that suggest tumor cell expression is a significant component for PD-L1, acting as a predictive biomarker for pembrolizumab (Keytruda) efficacy in patients with metastatic triple-negative breast cancer (mTNBC), according to a poster presented at the 38th Annual Miami Breast Cancer Conference, Physicians’ Education Resource®, LLC®.

More, the research suggests a significant number of responders were missed and overall survival (OS) benefits saw higher hazard ratio estimates when only immune cells were used to measure PD-L1 expression.

“Pembrolizumab monotherapy did not significantly improve overall survival (OS) compared with chemotherapy as second- or third-line treatment for patients with metastatic triple-negative breast cancer in the randomized, open-label, phase 3 KEYNOTE-119 study,” wrote the investigators. “However, the benefit of pembrolizumab compared with chemotherapy appeared to be greater with increasing PD-L1 expression, as quantified by combined positive score (CPS).”

Of the 622 patients enrolled in study, 601 had tumor samples that were available for the exploratory analysis. The patient population was randomized 1:1 to either the pembrolizumab arm (n = 309) or to the chemotherapy arm (n = 292).

In the pembrolizumab arm, the overall response rate was recorded at 9.7% (30 of 309 patients) versus 11.3% (33 of 292 patients) in the chemotherapy arm.

When comparing quantitative immune cell density (QID), tumor proportion score (TPS), and CPS, the featured scoring methods, the receiver operating characteristics (ROC) analysis found that CPS (0.69; 95% CI, 0.58-0.80) is better at enriching for responders better than both QID (0.66; 95% CI, 0.55-0.77) and TPS (0.55; 95% CI, 0.46-0.64) across all practical cutoffs.

Specifically, at each cutoff point, the research team observed that QID had both a lower estimated sensitivity and Youden Index than CPS, suggesting that immune cells measured with QID missed responders, not immune cells measured with CPS.

“Using a lower cutoff with QID to capture missed responders is not a viable solution because there will always be a CPS cutoff that detects at least as many responders as a QID cutoff but that misclassifies fewer nonresponders,” wrote the investigators.

In terms of the ORR advantage with CPS, there appears to be a translation with an OS benefit. Specifically, the hazard ratio for OS was slightly lower for CPS than it was for QID.

The data suggest that in tumor cells and immune cells, CPS should be utilized to quantify PD-L1 status for patients with mTNBC.

In regard to the scoring methods, TPS was defined by the research team as “the percentage of PD-L1‒expressing tumor cells (partial or complete membrane staining) relative to the total number of tumor cells.” More, CPS was “the number of PD-L1‒staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100” and QID was “CPS minus TPS.”

Patient eligibility required centrally confirmed mTNBC and those who underwent 1 or 2 systemic treatments for metastatic disease. Once deemed eligible, patients were then randomized 1:1 to receive either 200 mg of pembrolizumab every 3 weeks for up to 35 cycles or a single-agent chemotherapy including capecitabine, eribulin, gemcitabine, or vinorelbine.

“Emerging evidence has demonstrated that PD-L1 expression on tumor cells and immune cells is associated with better antitumor activity in response to immune checkpoint inhibitors in mTNBC,” wrote the investigators.

These results were previously reported at the Virtual 2020 San Antonio Breast Cancer Symposium, held December 8 through 12, 2020.


Emancipator K, Winer EP, Lipatov O, et al. Analysis From KEYNOTE-119 in Triple-Negative Breast Cancer (TNBC) Exploring the Contribution of Tumor and Immune Cells to PD-L1 as a Predictive Biomarker. Presented at: 38th Annual Miami Breast Cancer Conference® Virtual Conference; March 4-7, 2021. Poster 29.

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.